ROVI’s Alcalá de Henares plant receives the visit of the Romanian Health Minister

The Minister, Alexandru Rafila, was accompanied by the Director of Cabinet of the Romanian Ministry of Health and the Romanian Ambassador to Spain.


Madrid, 6th February, 2023

This Monday, the Romanian Minister of Health, Alexandru Rafila, visited the ROVI plant in Alcalá de Henares. The Chief of Staff of the Romanian Health Ministry, Raluca Puiu, and the Romanian ambassador to Spain, George Gabriel Bologan, were also present. The Romanian authorities were accompanied by ROVI’s Chairman and Chief Executive Officer, Juan López-Belmonte, the Industrial Manager, Miguel Ángel Ortega, and the Manager of the Alcalá de Henares plant, Pilar García-Morato Saro.

The ROVI plant in Alcalá de Henares is one of the Laboratory’s three plants engaged in the CMO (contract manufacturing organisation) business, the purpose of which is to respond to the growing need for pharmaceutical companies to outsource their manufacturing processes. The Alcalá plant specialises in the production of oral solid forms and has become a centre of excellence for the group’s packaging of both solid products and injectables.

ROVI is one of the main sector companies in the high value-added CMO business, with exports to over 50 countries. The majority of its sales are international and it is highly technologically specialised in the area of manufacturing vaccines, biological products and biosimilars, all of which are products with a recognised therapeutic value.

During the visit, the Romanian Health Minister, Alexandru Rafila, observed the plant’s manufacturing processes in detail and met with Juan López-Belmonte, the Chairman and Chief Executive Officer of ROVI.

Average: 1 (2 votes)
 
Related
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
Operating revenue increased by 23% to 101.0 million euros in the first quarter of 2020, mainly driven by the strength of the specialty...
7 min
13/05/2020
ROVI signs a co-operation agreement for a clinical trial to study the efficacy and safety of bemiparin in patients hospitalised with pneumonia caused by COVID-19
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has signed a co-operation agreement with Fundación de Investigación HM Hospitales to fund a...
2 min
14/04/2020
ROVI informs on the impact of Covid 19 on the company’s activities
Laboratorios Farmacéuticos ROVI, S.A. (ROVI) reports that, since the beginning of the spread of Covid-19, the company has been executing...
6 min
02/04/2020